These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
211 related articles for article (PubMed ID: 25065013)
41. Management of connective tissue diseases associated interstitial lung disease: a review of the published literature. Wallace B; Vummidi D; Khanna D Curr Opin Rheumatol; 2016 May; 28(3):236-45. PubMed ID: 27027811 [TBL] [Abstract][Full Text] [Related]
42. The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis. Khanna D; Berrocal VJ; Giannini EH; Seibold JR; Merkel PA; Mayes MD; Baron M; Clements PJ; Steen V; Assassi S; Schiopu E; Phillips K; Simms RW; Allanore Y; Denton CP; Distler O; Johnson SR; Matucci-Cerinic M; Pope JE; Proudman SM; Siegel J; Wong WK; Wells AU; Furst DE Arthritis Rheumatol; 2016 Feb; 68(2):299-311. PubMed ID: 26808827 [TBL] [Abstract][Full Text] [Related]
43. The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis. Khanna D; Berrocal VJ; Giannini EH; Seibold JR; Merkel PA; Mayes MD; Baron M; Clements PJ; Steen V; Assassi S; Schiopu E; Phillips K; Simms RW; Allanore Y; Denton CP; Distler O; Johnson SR; Matucci-Cerinic M; Pope JE; Proudman SM; Siegel J; Wong WK; Wells AU; Furst DE Arthritis Care Res (Hoboken); 2016 Feb; 68(2):167-78. PubMed ID: 26806474 [TBL] [Abstract][Full Text] [Related]
44. Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis-associated interstitial lung disease trials. Khanna D; Nagaraja V; Tseng CH; Abtin F; Suh R; Kim G; Wells A; Furst DE; Clements PJ; Roth MD; Tashkin DP; Goldin J Arthritis Res Ther; 2015 Dec; 17():372. PubMed ID: 26704522 [TBL] [Abstract][Full Text] [Related]
45. Systemic sclerosis: commonly asked questions by rheumatologists. Young A; Khanna D J Clin Rheumatol; 2015 Apr; 21(3):149-55. PubMed ID: 25807095 [TBL] [Abstract][Full Text] [Related]
46. Systemic sclerosis: a systematic review on therapeutic management from 2011 to 2014. Young A; Khanna D Curr Opin Rheumatol; 2015 May; 27(3):241-8. PubMed ID: 25775190 [TBL] [Abstract][Full Text] [Related]
47. Systemic sclerosis in 2014: Advances in cohort enrichment shape future of trial design. Allanore Y; Distler O Nat Rev Rheumatol; 2015 Feb; 11(2):72-4. PubMed ID: 25561368 [TBL] [Abstract][Full Text] [Related]
48. Old medications and new targeted therapies in systemic sclerosis. Nagaraja V; Denton CP; Khanna D Rheumatology (Oxford); 2015 Nov; 54(11):1944-53. PubMed ID: 25065013 [TBL] [Abstract][Full Text] [Related]
49. Update on disease-modifying antirheumatic drugs in the treatment of systemic sclerosis. Lin AT; Clements PJ; Furst DE Rheum Dis Clin North Am; 2003 May; 29(2):409-26. PubMed ID: 12841302 [TBL] [Abstract][Full Text] [Related]